What Is Better Than Wegovy for Weight Loss? Exploring Your Options

Last reviewed: July 7, 2026

Last updated: July 7, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy has become a household name in weight loss treatment, but it's not the only effective option—and it's not always the best fit for every patient. GLP-1 receptor agonists work by slowing stomach emptying and signaling fullness to the brain, yet individual response varies based on genetics, metabolism, and lifestyle. PlexusDx offers multiple compounded GLP-1 formulations and genetic testing to match you with the therapy most likely to work for your unique biology.

Why Some Patients Need Weight Loss Options Beyond Wegovy

Wegovy delivers effective results for many people, but approximately 30% of GLP-1 users experience inadequate response or intolerable side effects. Cost barriers, insurance delays, and supply shortages have also driven patients to seek alternatives. Additionally, some individuals have genetic predispositions that favor dual-pathway medications or different dosing schedules than Wegovy's standard tiered pen system.

PlexusDx recognizes that weight loss is not one-size-fits-all. Compounded semaglutide from licensed 503A pharmacies offers the same active ingredient as Wegovy but with flexible dosing, transparent pricing, and no insurance gatekeeping. For patients wanting broader metabolic support, tirzepatide (a dual GLP-1 and GIP receptor agonist) activates additional appetite-suppression pathways and may produce greater weight reduction in certain genetic profiles.

Compounded Semaglutide: Access and Affordability

Compounded semaglutide injection is manufactured by licensed 503A compounding pharmacies under pharmaceutical-grade standards and regulatory oversight. PlexusDx offers this option at $189/mo month-to-month, or from $149/mo on the 6-month plan, with the same active pharmaceutical ingredient as brand-name alternatives but without insurance requirements or membership fees. Your dose may need to go up over time as your body adapts, but your price won't—a transparent pricing model that removes the financial uncertainty many patients face.

Available in all 50 states and HSA/FSA eligible, compounded semaglutide provides the flexibility to adjust dose schedules based on your clinical response. Many patients achieve sustained weight loss and metabolic improvements within 3–6 months of consistent therapy. PlexusDx clinicians work with you to establish a starting dose and titration plan matched to your baseline health status and weight loss goals.

Tirzepatide and Dual-Action GLP-1 Therapy

Tirzepatide activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, a dual mechanism that often produces greater weight reduction than single-pathway GLP-1 agents alone. Clinical trials show tirzepatide users lose up to 22% of body weight over 68 weeks—a meaningful advantage for patients who have plateaued on semaglutide or seek more aggressive metabolic reshaping. PlexusDx offers compounded tirzepatide injection at $289/mo month-to-month, or from $249/mo on the 6-month plan or oral formulation at $349 per month.

The dual-pathway approach works particularly well for patients with genetic variants affecting GIP receptor sensitivity (GIPR rs1800437) or those with concurrent insulin resistance. Tirzepatide may also reduce cardiovascular risk and improve blood sugar control beyond weight loss alone. PlexusDx clinicians can discuss whether tirzepatide aligns with your metabolic profile and treatment history.

Genetic Testing for Precision GLP-1 Therapy

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Added for $99 after your first month of treatment, the Precision Peptide Genetic Test helps PlexusDx clinicians tailor your dose, formulation, and combination therapy to your genetic predispositions. Patients with favorable GLP1R markers may require lower doses for symptom control, while those with FTO risk variants may benefit from dual-pathway therapy or microdose protocols to minimize nausea during the titration phase.

Choosing Between Injectable and Oral Formulations

PlexusDx offers both injectable and oral versions of semaglutide and tirzepatide, giving you flexibility based on lifestyle and preference. Injectable formulations achieve faster peak blood levels and are often preferred by patients seeking rapid symptom onset and predictable dosing. Oral semaglutide (at $289/mo month-to-month, or from $249/mo on the 6-month plan) and oral tirzepatide (at $349/mo month-to-month, or from $279/mo on the 6-month plan) appeal to injection-averse patients and those with frequent travel or needle phobias.

Absorption and bioavailability differ between routes; injectables generally produce more consistent drug levels, while oral absorption can be affected by stomach pH and food intake. Your PlexusDx clinician will discuss which route aligns with your clinical needs and personal preferences during your initial consultation. Both pathways support sustainable weight loss when paired with behavioral modification and consistent medication adherence.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide as safe and effective as brand-name Wegovy?

Yes. Compounded semaglutide from PlexusDx comes from licensed 503A compounding pharmacies operating under FDA oversight and pharmaceutical-grade standards. The active ingredient is identical to Wegovy; the difference is manufacturing source and pricing model. Clinical outcomes are comparable when dosed appropriately and monitored by a qualified clinician.

What does the Precision Peptide Genetic Test reveal?

The test analyzes 14 metabolic pathways and 150+ genetic insights to map your peptide-pathway predispositions, not just pharmacogenomic drug metabolism. It reveals how your GLP1R, GIPR, FTO, and MC4R variants influence appetite control, satiety signaling, and baseline metabolic rate—insights that help PlexusDx clinicians recommend the formulation and dose most likely to work for your unique biology.

Does PlexusDx require insurance or membership fees?

No. PlexusDx serves all 50 states with no insurance requirement, no membership fees, and no hidden charges. All medications are HSA/FSA eligible, and pricing is flat across commitment tiers—your dose may increase, but your monthly price remains constant at your enrolled tier.

What are common side effects of GLP-1 therapy, and how do you manage them?

Nausea, vomiting, constipation, and appetite suppression are common during the first 2–4 weeks as your body adapts. PlexusDx clinicians use low-starting doses and gradual titration to minimize side effects while building tolerance. Hydration, dietary fiber, and anti-nausea strategies are discussed at each visit; most side effects resolve by week 6.

Should I choose semaglutide, tirzepatide, or the dual-pathway GLP-Squared protocol?

The choice depends on your genetics, weight loss history, and metabolic markers. Semaglutide is ideal for first-time GLP-1 users or those with mild-to-moderate obesity; tirzepatide suits patients seeking aggressive weight reduction or those with insulin resistance. GLP-Squared (dual semaglutide + tirzepatide, starting at $289/month for injection) targets advanced cases; genetic testing via the Precision Peptide test helps clarify which option matches your biology best.

Related Reading

• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss
• Wegovy Weight Loss

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.